BI Asset Management Fondsmaeglerselskab A S Cuts Stake in Insulet Corporation $PODD

BI Asset Management Fondsmaeglerselskab A S lowered its stake in shares of Insulet Corporation (NASDAQ:PODD) by 52.0% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 14,663 shares of the medical instruments supplier’s stock after selling 15,871 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S’s holdings in Insulet were worth $3,077,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the stock. Glenmede Investment Management LP boosted its position in shares of Insulet by 1.6% during the third quarter. Glenmede Investment Management LP now owns 2,292 shares of the medical instruments supplier’s stock worth $708,000 after acquiring an additional 35 shares during the last quarter. Curi Capital LLC increased its holdings in Insulet by 0.8% in the 2nd quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock valued at $1,365,000 after acquiring an additional 36 shares during the last quarter. WINTON GROUP Ltd lifted its stake in Insulet by 0.9% in the 3rd quarter. WINTON GROUP Ltd now owns 4,086 shares of the medical instruments supplier’s stock worth $1,261,000 after purchasing an additional 37 shares in the last quarter. Great Lakes Advisors LLC lifted its stake in Insulet by 1.5% in the 4th quarter. Great Lakes Advisors LLC now owns 2,784 shares of the medical instruments supplier’s stock worth $791,000 after purchasing an additional 40 shares in the last quarter. Finally, Camarda Financial Advisors LLC boosted its holdings in shares of Insulet by 0.5% during the 2nd quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier’s stock valued at $2,304,000 after purchasing an additional 40 shares during the last quarter.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. BTIG Research cut their price objective on Insulet from $260.00 to $235.00 and set a “buy” rating for the company in a research report on Tuesday, May 26th. Jefferies Financial Group decreased their target price on Insulet from $400.00 to $360.00 in a research report on Thursday, May 7th. The Goldman Sachs Group reissued a “buy” rating and set a $205.00 price target on shares of Insulet in a research note on Wednesday, May 27th. Bank of America cut their price target on Insulet from $288.00 to $208.00 and set a “buy” rating for the company in a report on Monday, May 18th. Finally, Rothschild & Co Redburn reaffirmed a “neutral” rating and issued a $220.00 price objective (down from $380.00) on shares of Insulet in a research note on Friday, April 24th. Twenty-one equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $240.78.

Insulet Stock Performance

Shares of NASDAQ:PODD opened at $138.97 on Tuesday. Insulet Corporation has a 52 week low of $138.79 and a 52 week high of $354.88. The stock has a market capitalization of $9.63 billion, a P/E ratio of 32.32, a PEG ratio of 1.15 and a beta of 1.13. The firm has a fifty day simple moving average of $162.97 and a two-hundred day simple moving average of $224.47. The company has a quick ratio of 1.81, a current ratio of 2.49 and a debt-to-equity ratio of 0.71.

Insulet (NASDAQ:PODD) last announced its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.19 by $0.23. The firm had revenue of $761.70 million for the quarter, compared to analysts’ expectations of $729.89 million. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The business’s revenue was up 33.9% compared to the same quarter last year. During the same period in the prior year, the company earned $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, analysts expect that Insulet Corporation will post 6.46 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Timothy C. Stonesifer acquired 2,790 shares of Insulet stock in a transaction on Wednesday, June 3rd. The shares were bought at an average cost of $143.51 per share, with a total value of $400,392.90. Following the completion of the purchase, the director directly owned 9,041 shares of the company’s stock, valued at $1,297,473.91. The trade was a 44.63% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.36% of the stock is owned by insiders.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.